Press Release

30 May 2017

Immunicum AB (publ) Announces Participation at Conferences in June

Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that Carlos de Sousa, MD, CEO of Immunicum, has been invited to present the Company at several upcoming conferences in June and t o participate on a panel titled "New Frontiers in Oncology". In addition, the Company will attend the 2017 BIO International Convention.

Sachs Associates 3rd Annual Immuno-Oncology BD&L and Investment Forum
Date: June 2, 2017
Presentation Time: 11:10 am Central Standard Time
Venue: Hyatt Centric Chicago Magnificent Mile Hotel, Chicago, Illinois

Labiotech Refresh
Date: June 8, 2017
Panel: "New Frontiers in Oncology" 10:30 am Central European Time
Venue: Spreewerkstätten, Berlin, Germany

Småbolagsdagen
Date: June 12, 2017
Presentation Time: 9:20 - 9:50 am Central European Time
Venue: Sheraton Hotel Stockholm, Stockholm, Sweden

For those who can't participate, the presentation from Småbolagsdagen will be available afterwards on Immunicum's website and will also be broadcasted live on www.smabolagsdagen.net

2017 BIO International Convention (attendance only)
Date: June 19-22, 2017
Venue: San Diego Convention Center, San Diego, California

For more information, please contact:

Carlos de Sousa, VD, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com

Investor Relations Sweden

Helena Stångberg
Hallvarsson & Halvarsson
Telephone: + 46 709 71 12 53
E-mail: helena.stangberg@halvarsson.se

Investor and Media Relations EU/US

MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Telephone: +49 89 2424 3494 or +49 175 5711562
E-mail: gschweitzer@macbiocom.com or smay@macbiocom.com

The Company's Certified Adviser is Redeye AB
Telephone: +46 (0) 8 545 013 31
www.redeye.se

 

 

About Immunicum AB (publ) Immunicum AB (First North Premier: IMMU.ST) is a clinical stage Company developing novel immuno-oncology therapies against a range of solid tumors. The Company's lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body. www.immunicum.com